Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant varicella vaccine
- Development stage
- Preclinical
- Lead developer
- Zydus Lifesciences
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The recombinant varicella vaccine is a prophylactic vaccine candidate being developed by Zydus Lifesciences for the prevention of chickenpox (varicella). This vaccine utilizes recombinant DNA technology to produce specific antigens of the varicella-zoster virus (VZV), such as viral glycoproteins, to stimulate a protective immune response. Unlike traditional live-attenuated varicella vaccines, this recombinant subunit approach does not contain live virus, potentially offering a safer alternative for individuals with compromised immune systems. The project is currently in the preclinical stage of development.
- Other names
- recombinant varicella vaccineZydus varicella vaccinerecombinant varicella antigen vaccine
Beyond the preview
Go deeper on recombinant varicella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant varicella vaccine.